Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 4/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | ESR1 | P03372 | 1/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | PDE4A | P27815 | 1/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.45 |
| ▸ | STAT6 | P42226 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13600083 | 0.84 | MAPT (0.52) | MAPTKDM4EPOLBPKMRAB9A | |
| SCHEMBL30041537 | 0.84 | MAPT (0.52) | MAPTKDM4EPOLBPKMRAB9A | |
| SCHEMBL23535674 | 0.84 | MAPT (0.52) | MAPTKDM4EPOLBPKMRAB9A | |
| SCHEMBL1749736 | 0.82 | SLC6A3 (0.44) | KDM4EPOLBTSHRCYP3A4ABCB11 | |
| SCHEMBL6653937 | 0.79 | CA1 (0.57) | MAPTKDM4ERAB9ATSHRALDH1A1 | |
| SCHEMBL3919432 | 0.77 | CA1 (0.47) | MAPTKDM4ERAB9ASMN1; SMN2TSHR | |
| SCHEMBL3647221 | 0.76 | MAPT (0.57) | MAPTKDM4EPOLBPKMRAB9A | |
| SCHEMBL14962071 | 0.74 | SLC6A2 (0.63) | KDM4ERAB9ATSHRCYP3A4LMNA | |
| SCHEMBL8531240 | 0.74 | ALOX15 (0.50) | MAPTKDM4EPOLBPKMRAB9A | |
| SCHEMBL3560642 | 0.74 | HDAC1 (0.56) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102964294-A | Pyridyl inhibitors of hedgehog signalling | GENENTECH INC | 2013-03-13 | — | — | CN | disclosed |
| CN-102083822-A | Pyridyl inhibitors of HEDGEHOG signalling | GENENTECH INC | 2011-06-01 | — | — | CN | disclosed |
| US-7495022-B2 | α,β-unsaturated hydroxamic acid derivatives and their use as histone deacetylase inhibitors | SK CHEMICALS CO., LTD. (KR) | 2009-02-24 | — | — | US | disclosed |
| CN-101072755-A | Pyridyl inhibitors of Hedgehog signaling | GENENTECH INC (US) | 2007-11-14 | — | — | CN | disclosed |
| US-20050124679-A1 | Alpha, beta-unsaturated hydroxamic acid derivatives and their use as histone deacetylase inhibitors | SK CHEMICALS CO., LTD. (KR) | 2005-06-09 | — | — | US | disclosed |
| WO-2003087066-A1 | α,β-UNSATURATED HYDROXAMIC ACID DERIVATIVES AND THEIR USE AS HISTONE DEACETYLASE INHIBITORS | SK CHEMICALS, CO., LTD. (KR) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124679-A1 | Alpha, beta-unsaturated hydroxamic acid derivatives and their use as histone deacetylase inhibitors | HDAC1, HDAC5, HDAC9 | MAPT 4083/4885KDM4E 1744/4885POLB 589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.